drugset

drugset / Trial / NCT00830895

RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

NCT00830895 ↗

Phase 2 Completed 49 enrolled Seoul National University Hospital

NaSingle-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma

Timeline

Start: 2009-01
Primary completion: 2010-10
Completion: 2012-12

Publications

Koh Y, Lim HY, Ahn JH, Lee JL, Rha SY, Kim YJ, Kim TM, Lee SH. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol. 2013 Apr;24(4):1026-31. doi: 10.1093/annonc/mds582. Epub 2012 Nov 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	10 mg	—

Indications